IDH-mutant astrocytomas usually receive radiotherapy in conjunction with adjuvant temozolomide (TMZ), whereas glioblastomas receive radiotherapy and either concurrent or adjuvant TMZ [3]. This evidence concerns the gene IDH1 and astrocytoma (excluding glioblastoma).